MicroRNA expression, survival, and response to interferon in liver cancer.

BACKGROUND Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in men. We examined microRNA expression patterns, survival, and response to interferon alfa in both men and women with the disease. METHODS We analyzed three independent cohorts that included a total of 455 patients with hepatocellular carcinoma who had undergone radical tumor resection between 1999 and 2003. MicroRNA-expression profiling was performed in a cohort of 241 patients with hepatocellular carcinoma to identify tumor-related microRNAs and determine their association with survival in men and women. In addition, to validate our findings, we used quantitative reverse-transcriptase-polymerase-chain-reaction assays to measure microRNAs and assess their association with survival and response to therapy with interferon alfa in 214 patients from two independent, prospective, randomized, controlled trials of adjuvant interferon therapy. RESULTS In patients with hepatocellular carcinoma, the expression of miR-26a and miR-26b in nontumor liver tissue was higher in women than in men. Tumors had reduced levels of miR-26 expression, as compared with paired noncancerous tissues, which indicated that the level of miR-26 expression was also associated with hepatocellular carcinoma. Moreover, tumors with reduced miR-26 expression had a distinct transcriptomic pattern, and analyses of gene networks revealed that activation of signaling pathways between nuclear factor kappaB and interleukin-6 might play a role in tumor development. Patients whose tumors had low miR-26 expression had shorter overall survival but a better response to interferon therapy than did patients whose tumors had high expression of the microRNA. CONCLUSIONS The expression patterns of microRNAs in liver tissue differ between men and women with hepatocellular carcinoma. The miR-26 expression status of such patients is associated with survival and response to adjuvant therapy with interferon alfa.

[1]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[2]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[3]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[4]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[5]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[6]  R. Fry,et al.  Hepatocellular carcinoma associated with liver-gender disruption in male mice. , 2007, Cancer research.

[7]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[8]  T. Asahara,et al.  Sex Hormone Dependency of Diethylnitrosamine‐induced Liver Tumors in Mice and Chemoprevention by Leuprorelin , 2001, Japanese journal of cancer research : Gann.

[9]  Tetsuo Sumi,et al.  Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor , 2005, Gastric Cancer.

[10]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[11]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[12]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[13]  S. Fan,et al.  Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach , 1995 .

[14]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[15]  Dan Grandér,et al.  Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. , 2007, Experimental cell research.

[16]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[17]  X. Wang,et al.  Cancer‐associated molecular signature in the tissue samples of patients with cirrhosis , 2004, Hepatology.

[18]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[19]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[20]  S. Fan,et al.  A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular Carcinoma , 2007, Annals of surgery.

[21]  L. Gallagher.  Hepatitis B. , 2016, Journal.

[22]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[23]  J. Wands.  Hepatocellular carcinoma and sex. , 2007, The New England journal of medicine.

[24]  P. Clavien.  Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? , 2007, Annals of surgery.

[25]  Q. Ye,et al.  Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial , 2006, Journal of Cancer Research and Clinical Oncology.

[26]  S. Fan,et al.  Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. , 1995, Cancer.

[27]  P. Tangkijvanich,et al.  Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[28]  N. Ghebranious,et al.  Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice , 1998, Hepatology.

[29]  H. Ishibashi,et al.  Longer survival in female than male with hepatocellular carcinoma , 2003, Journal of gastroenterology and hepatology.

[30]  C. Porta,et al.  Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.